Early stage medical device company Phraxis has raised approximately $5.6 million in a new round of equity and options financing, according to a recently posted SEC filing. Phraxis is developing a novel treatment for patients who need vascular access for hemodialysis, according to the company’s website. The St. Paul, Minn.-based company’s first product for commercialization […]
Baxter International Inc. (NYSE: BAX) put aside $200 million in equity to invest in early-stage companies that "complement" its portfolio.
The newly established " Baxter Ventures will invest globally and focus on innovative technologies with sustainable long-term growth" under the watch of the Deerfield, Ill.-based company’s chief scientific officer Norbert Riedel, according to a press release.